J&J, Regeneron follow Pfizer in clinical holds for anti-NGFs
This article was originally published in Scrip
Executive Summary
The US FDA last week placed clinical holds on the testing of two separate investigational anti-nerve growth factor (NGF) pain drugs under development by Johnson & Johnson and Regeneron Pharmaceuticals and its partner Sanofi-Aventis after a case of avascular necrosis of a joint was confirmed in a clinical trial participant.
You may also be interested in...
Pfizer/Lilly Discontinue Tanezumab, The Likely End For A Class Dogged By Safety
The nerve growth factor inhibitor for osteoarthritis pain is one of the last still in development after safety largely sidetracked the class of drugs.
Surprise! Pfizer And Lilly File Tanezumab For Pain With FDA Despite Safety Questions
The partners have filed the first-in-class NGF inhibitor at the lower 2.5mg dose for the treatment of osteoarthritis pain, despite the drug’s challenging safety profile.
Pfizer, Lilly Weigh In On Dosing And Safety Of Non-Opioid Pain Drug Tanezumab
Two dosing regimens hit the mark on three co-primary endpoints and the rate of rapidly progressive osteoarthritis was low at 1.3% in a Phase III study of the NGF inhibitor presented on Oct. 23.